X4 Pharmaceuticals (XFOR) Fundamentals 2026 — Revenue Analysis | SniperIQ
X4 Pharmaceuticals (XFOR) is a US-listed Healthcare company in Biotechnology with a market capitalization of
X4 Pharmaceuticals (XFOR) has a market capitalization of approximately
X4 Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
X4 Pharmaceuticals runs a net profit margin of -1106.3%, a gross margin of 79.4%, and an operating margin of -1084.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
X4 Pharmaceuticals reported revenue of
X4 Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
X4 Pharmaceuticals carries a debt-to-equity ratio of 0.46x and a current ratio of 10.18x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For X4 Pharmaceuticals (XFOR) the key facts are: market cap
Get X4 Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.